Welcome
Select Area of Interest
Blank Space
Choose topic:
FAQs
Epidemiology
Pathology
Diagnosis
Control
Prevention
Herd/Flock Management
Laws & Regulations
True Cases & Stories
Gallery Graphics
Line
General Information
Glossary
History
Biology of Ml. Paratuberculosis
Antimicrobial Therapy
Zoonotic Potential
Handouts/Brochures
Links

Testing Services
Guestbook
Sponsors & Credits
Ask the Expert
Site Map
Search the Site
Home
Blank Space
HISTORY
JOHNE'S INFORMATION CENTER - University of Wisconsin Ñ School of Veterinary Medicine



Bar
Tuesday, July 31, 2018
MAP & Crohn’s & RedHill BioPharma – more details.

This news item provides a copy of a press release from RedHill BioPharma that gives more details about their clinical trial findings. Key findings:

  • Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013).

  • Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104.

  • Comment: The real proof is in the final peer reviewed publication: Repeating comments from the prior new item, if the final published results of this trial are consistent with the claims in this press release, it represents a final piece of evidence indicating that MAP is a cause of Crohn’s disease. This would heighten the need for veterinary medicine, animal agriculture, and relevant governmental agencies concerned with food safety to limit contamination of food and water by MAP.

    Press Release